Splenectomy in myelofibrosis with myeloid metaplasia: A single- institution experience with 223 patients

Blood

Volumn 95, Issue 7, 2000, Pages 2226-2233

  Tefferi, Ayalew ^a   Mesa, Ruben A ^b   Nagorney, David M ^b   Schroeder, Georgene ^b   Silverstein, Murray N ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLAST TRANSFORMATION; CANCER REGRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYELOFIBROSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; SPLENECTOMY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 0034176014     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.7.2226.007k19_2226_2233     Document Type: Article

References (60)

1. Tefferi A, Silverstein MN, Noel P. Agnogenic myeloid metaplasia. Semin Oncol. 1995;22:327.
2. Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev. 1997;11:233.
3. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol. 1997;97:441.
4. Martyre MC. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma. 1995;20:39.
5. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer. 1997;80:708
6. Thiele J, Windecker R, Kvasnicka HM, Titius BR, Zankovich R, Fischer R. Erythropoiesis in primary (idiopathic) osteomyelofibrosis: quantification, PCNA-reactivity, and prognostic impact. Am J Hematol. 1994;46:36.
7. Wolf BC, Banks PM, Mann RB, Neiman RS. Splenic hematopoiesis in polycythemia vera: a morphologic and immunohistologic study. Am J Clin Pathol. 1988;89:69.
8. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013.
9. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4.
10. Thiele J, Steinberg T, Zankovich R, Fischer R. Primary myelofibrosis-osteomyelosclerosis (agnogenic myeloid metaplasia): correlation of clinical findings with bone marrow histopathology and prognosis. Anticancer Res. 1989;9:429.
11. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol. 1988;70:397.
12. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E. The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol. 1998;60:101.
13. Silverstein MN. Agnogenic Myeloid Metaplasia. Acton, MA: Publishing Sciences Group; 1975.
14. Besa EC, Nowell PC, Geller NL, Gardner FH. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer. 1982;49:308.
15. Levy V, Bourgarit A, Delmer A, et al. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. Am J Hematol. 1996;53:239.
16. Barosi G, Liberato LN, Costa A, Ascari E. Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut. 1989;58:271.
17. Sacchi S. The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update, Leuk Lymphoma. 1995;19:13.
18. Tefferi A, Silverstein MN. Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia [letter]. Br J Haematol. 1994;86:893.
19. Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol. 1997;98:1010.
20. Guardiola P, Esperou H, Cazals-Hatem D, et al, for the French Society of Bone Marrow Transplantation. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol. 1997;98:1004.
21. Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol. 1988;41:375.
22. Najean Y, Arrago JP, Rain JD, Dresch C. The 'spent' phase of polycythaemia vera: hypersplenism in the absence of myelofibrosis. Br J Haematol. 1984;56:163.
23. Barosi G, Baraldi A, Cazzola M, et al. Polycythaemia following splenectomy in myelofibrosis with myeloid metaplasia: a reorganization of erythropoiesis. Scand J Haematol. 1984;32:12.
24. Douay L, Laporte JP, Lefrancois G, et al. Blood and spleen haematopoiesis in patients with myelofibrosis. Leuk Res. 1987;11:725.
25. Tavassoli M, Weiss L. An electron microscopic study of spleen In myelofibrosis with myeloid metaplasia. Blood. 1973;42:257.
26. Beguin Y, Fillet G, Bury J, Fairon Y. Ferrokinetic study of splenic erythropoiesis: relationships among clinical diagnosis, myelofibrosis, splenomegaly, and extramedullary erythropoiesis. Am J Hematol. 1989;32:123.
27. Thiele J, Bennewitz FG, Bertsch HP, Falk S, Fischer R, Stutte HJ. Splenic haematopoiesis in primary (idiopathic) osteomyelofibrosis: immunohistochemical and morphometric evaluation of proliferate activity of erythro- and endoreduplicative capacity of megakaryopoiesis (PCNA- and Ki-67 staining). Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64:281.
28. Sjögren U. Different composition of the erythropoietic tissue in bone marrow, spleen and liver in myelofibrosis. Acta Haematol. 1978;59:231.
29. Pettit JE, Lewis SM, Williams ED, Grafton CA, Bowring CS, Glass HI. Quantitative studies of splenic erythropoiesis in polycythaemia vera and myelofibrosis. Br J Haematol. 1976;34:465.
30. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998;103:505.
31. Lafaye F, Rain JD, Clot P, Najean Y. Risks and benefits of splenectomy in myelofibrosis: an analysis of 39 cases. Nouv Rev Fr Hemalol. 1994;36:359.
32. Barosi G, Ambrosetti A, Buratti A, et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia. 1993;7:200.
33. Benbassat J, Gilon D, Penchas S. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. Am J Hematol. 1990;33:128.
34. Brenner B, Nagler A, Tatarsky I, Hashmonai M. Splenectomy in agnogenic myeloid metaplasia and postpolycythemic myeloid metaplasia: a study of 34 cases. Arch Intern Med. 1988;148: 2501.
35. Jarvinen H, Kivilaakso E, Ikkala E, Vuopio P, Hastbacka J. Splenectomy for myelofibrosis. Ann Clin Res. 1982;14:66.
36. Coon WW, Liepman MK. Splenectomy for agnogenic myeloid metaplasia. Surg Gynecol Obstet. 1982;154:561.
37. Benbassat J, Penchas S, Ligumski M. Splenectomy in patients with agnogenic myeloid metaplasia: an analysis of 321 published cases Br J Hematol. 1979;42:207.
38. Silverstein MN, ReMine WH. Splenectomy in myeloid metaplasia. Blood. 1979;53:515.
39. Cabot EB, Brennan MF, Rosenthal DS, Wilson RE. Splenectomy in myeloid metaplasia. Ann Surg. 1978;187:24.
40. Mulder H, Steenbergen J, Haanen C. Clinical course and survival after elective splenectomy in 19 patients with primary myelolibrosis. Br J Haematol. 1977;35:419.
41. Jacobs P. Splenectomy and myelofibrosis. S Afr Med J. 1976;50:550.
42. Morgenstern L. Splenectomy tor massive splenomegaly due to myeloid metaplasia. Am J Surg. 1971;122:288.
43. Marks C, Ahmadi M. Agnogenic myeloid metaplasia: role of splenectomy. Postgrad Med J. 1969; 45:261.
44. Gomes MR, Silverstein MN, Remine WH. Splenectomy for agnogenic myeloid metaplasia. Surg Gynecol Obstel. 1967;125:106.
45. Hickling RA. Chronic non-leukaemic myelosis. Q J Med. 1937;36:253.
46. Benbassat J, Penchas S. 'Early' splenectomy and survival in agnogenic myeloid metaplasia: an analysis of 338 cases published since 1940. Acta Haematol. 1981;65:189.
47. Michiels JJ. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia. Neth J Med. 1997;51:57.
48. Dickstein JI, Vardiman JW. Hematopathologic findings in the myeloproliferative disorders. Semin Oncol. 1995;22:355.
49. Tefferi A, Barrett SM, Silverstein MN, Nagomey DM. Outcome of portal-systemic shunt surgery for portal hypertension associated with intrahepatic obstruction in patients with agnogenic myeloid metaplasia. Am J Hematol. 1994;46:325.
50. Lopez-Guillermo A, Cervantes F, Bruguera M, Pereira A, Feliu E, Rozman C. Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematol. 1991;85: 184.
51. Wanless IR, Peterson P, Das A, Boitnott JK, Moore GW, Bernier V. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology. 1990;12:1166.
52. Tefferi A, Silverstein MN, Li CY. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol. 1997;99:352.
53. Chaftanjon PC, Brichon PY, Ranchoup Y, Gressin R, Sotto JJ. Portal vein thrombosis following spleneclomy for hematologic disease: prospective study with Doppler color flow imaging. World J Surg. 1998;22:1082.
54. Aviram M, Carter A, Tatarsky I, Levy Y, Brook JG. Increased platelet aggregation following splenectomy in patients with myeloproliferative disease. Isr J Med Sci. 1985;21:415.
55. Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis: a clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore). 1983;62:353.
56. Chelloul N, Briere J, Laval-Jeantet M, Najean Y, Vorhauer W, Jacquillat C. Prognosis of myeloid metaplasia with myelofibrosis. Biomedicine. 1976:24:272.
57. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635.
58. Rupoli S, Da Lio L, Sisti S, et al. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol. 1994;68:205.
59. Barosi G, Ambrosetti A, Centra A, et al, for the Italian Cooperative Study Group on Myelofibrosis with Myeloid Metaplasia. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood. 1998;91:3630.
60. Porcu P, Neiman RS, Orazi A. Splenectomy in agnogenic myeloid metaplasia [letter]. Blood 1999;93:2132.